Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Capital Leases (2016 - 2018)

Historic Capital Leases for Ironwood Pharmaceuticals (IRWD) over the last 10 years, with Q4 2018 value amounting to $158000.0.

  • Ironwood Pharmaceuticals' Capital Leases changed N/A to $158000.0 in Q4 2018 from the same period last year, while for Dec 2018 it was $158000.0, marking a year-over-year change of. This contributed to the annual value of $158000.0 for FY2018, which is N/A changed from last year.
  • Per Ironwood Pharmaceuticals' latest filing, its Capital Leases stood at $158000.0 for Q4 2018.
  • In the past 5 years, Ironwood Pharmaceuticals' Capital Leases ranged from a high of $3.2 million in Q2 2014 and a low of $21000.0 during Q1 2017
  • Its 5-year average for Capital Leases is $1.3 million, with a median of $687000.0 in 2015.
  • As far as peak fluctuations go, Ironwood Pharmaceuticals' Capital Leases surged by 149494.95% in 2014, and later tumbled by 9169.96% in 2017.
  • Over the past 5 years, Ironwood Pharmaceuticals' Capital Leases (Quarter) stood at $2.6 million in 2014, then tumbled by 88.1% to $306000.0 in 2015, then crashed by 73.2% to $82000.0 in 2016, then plummeted by 74.39% to $21000.0 in 2017, then skyrocketed by 652.38% to $158000.0 in 2018.
  • Its Capital Leases was $158000.0 in Q4 2018, compared to $21000.0 in Q1 2017 and $82000.0 in Q4 2016.